CN106389892A - 一种食疗粉及其制备方法 - Google Patents
一种食疗粉及其制备方法 Download PDFInfo
- Publication number
- CN106389892A CN106389892A CN201611029647.2A CN201611029647A CN106389892A CN 106389892 A CN106389892 A CN 106389892A CN 201611029647 A CN201611029647 A CN 201611029647A CN 106389892 A CN106389892 A CN 106389892A
- Authority
- CN
- China
- Prior art keywords
- powder
- rhizoma gastrodiae
- radix
- preparation
- radix notoginseng
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000843 powder Substances 0.000 title claims abstract description 117
- 238000002560 therapeutic procedure Methods 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 235000013305 food Nutrition 0.000 title abstract description 8
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 45
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 45
- 239000009636 Huang Qi Substances 0.000 claims abstract description 36
- 239000002994 raw material Substances 0.000 claims abstract description 15
- 241001076416 Dendrobium tosaense Species 0.000 claims abstract description 13
- 235000005911 diet Nutrition 0.000 claims description 30
- 230000000378 dietary effect Effects 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 238000002156 mixing Methods 0.000 claims description 18
- 235000006533 astragalus Nutrition 0.000 claims description 13
- 241000045403 Astragalus propinquus Species 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 238000001035 drying Methods 0.000 claims description 10
- 244000017020 Ipomoea batatas Species 0.000 claims description 8
- 235000002678 Ipomoea batatas Nutrition 0.000 claims description 8
- 238000001291 vacuum drying Methods 0.000 claims description 8
- 239000011812 mixed powder Substances 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- 238000010025 steaming Methods 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 abstract description 49
- 239000008280 blood Substances 0.000 abstract description 49
- 230000000694 effects Effects 0.000 abstract description 44
- 239000003814 drug Substances 0.000 abstract description 38
- 230000036772 blood pressure Effects 0.000 abstract description 12
- 230000006870 function Effects 0.000 abstract description 12
- 230000001737 promoting effect Effects 0.000 abstract description 11
- 210000004185 liver Anatomy 0.000 abstract description 10
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 9
- 206010020772 Hypertension Diseases 0.000 abstract description 9
- 230000036039 immunity Effects 0.000 abstract description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract description 8
- 208000002173 dizziness Diseases 0.000 abstract description 7
- 208000029078 coronary artery disease Diseases 0.000 abstract description 6
- 206010019468 Hemiplegia Diseases 0.000 abstract description 5
- 206010028980 Neoplasm Diseases 0.000 abstract description 5
- 208000024827 Alzheimer disease Diseases 0.000 abstract description 4
- 241000305491 Gastrodia elata Species 0.000 abstract description 4
- 102000004877 Insulin Human genes 0.000 abstract description 4
- 108090001061 Insulin Proteins 0.000 abstract description 4
- 206010039966 Senile dementia Diseases 0.000 abstract description 4
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract description 4
- 210000000988 bone and bone Anatomy 0.000 abstract description 4
- 201000001421 hyperglycemia Diseases 0.000 abstract description 4
- 206010022437 insomnia Diseases 0.000 abstract description 4
- 229940125396 insulin Drugs 0.000 abstract description 4
- 238000005728 strengthening Methods 0.000 abstract description 4
- 210000002435 tendon Anatomy 0.000 abstract description 4
- 238000005516 engineering process Methods 0.000 abstract description 3
- 230000004438 eyesight Effects 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 3
- 210000002784 stomach Anatomy 0.000 abstract description 3
- 206010003210 Arteriosclerosis Diseases 0.000 abstract description 2
- 208000032928 Dyslipidaemia Diseases 0.000 abstract description 2
- 201000005569 Gout Diseases 0.000 abstract description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract description 2
- 208000019914 Mental Fatigue Diseases 0.000 abstract description 2
- 208000008589 Obesity Diseases 0.000 abstract description 2
- 206010000059 abdominal discomfort Diseases 0.000 abstract description 2
- 230000003213 activating effect Effects 0.000 abstract description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract description 2
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 239000012530 fluid Substances 0.000 abstract description 2
- 230000001050 lubricating effect Effects 0.000 abstract description 2
- 230000004060 metabolic process Effects 0.000 abstract description 2
- 235000020824 obesity Nutrition 0.000 abstract description 2
- 241000208689 Eucommia ulmoides Species 0.000 abstract 1
- 238000012994 industrial processing Methods 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 238000011127 radiochemotherapy Methods 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 230000003860 sleep quality Effects 0.000 abstract 1
- 230000036541 health Effects 0.000 description 17
- 230000007812 deficiency Effects 0.000 description 15
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 12
- 239000008103 glucose Substances 0.000 description 12
- 150000004676 glycans Chemical class 0.000 description 11
- 229920001282 polysaccharide Polymers 0.000 description 11
- 239000005017 polysaccharide Substances 0.000 description 11
- 206010019233 Headaches Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 231100000869 headache Toxicity 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 230000017531 blood circulation Effects 0.000 description 8
- 230000007774 longterm Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 241000272522 Anas Species 0.000 description 6
- 241000272814 Anser sp. Species 0.000 description 6
- 102000002322 Egg Proteins Human genes 0.000 description 6
- 108010000912 Egg Proteins Proteins 0.000 description 6
- 241000628997 Flos Species 0.000 description 6
- 206010030113 Oedema Diseases 0.000 description 6
- 208000033809 Suppuration Diseases 0.000 description 6
- 238000010411 cooking Methods 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 210000004681 ovum Anatomy 0.000 description 6
- 235000019640 taste Nutrition 0.000 description 6
- 241000208340 Araliaceae Species 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 5
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 5
- 235000003140 Panax quinquefolius Nutrition 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 235000008434 ginseng Nutrition 0.000 description 5
- -1 lipid peroxide Chemical class 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 206010007247 Carbuncle Diseases 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 102000019197 Superoxide Dismutase Human genes 0.000 description 4
- 108010012715 Superoxide dismutase Proteins 0.000 description 4
- 244000269722 Thea sinensis Species 0.000 description 4
- 230000003712 anti-aging effect Effects 0.000 description 4
- 210000003414 extremity Anatomy 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000000582 semen Anatomy 0.000 description 4
- 206010040872 skin infection Diseases 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 206010002383 Angina Pectoris Diseases 0.000 description 3
- 101100381997 Danio rerio tbc1d32 gene Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 101100381999 Mus musculus Tbc1d32 gene Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 210000004351 coronary vessel Anatomy 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000004224 protection Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 230000035900 sweating Effects 0.000 description 3
- RYHZSFNAGFOCEZ-PYXKSNNZSA-N (2r,3r,4s,5s,6r)-4-[(3r,4s,5s,6r)-6-[[(2r,3r,4s,5s,6r)-4-[(2s,3r,4s,5r,6r)-6-[[(2r,3r,4r,5s)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4,5-trihydroxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]-4-[(3r,4s,5r,6r)-6-[[(2r,3 Chemical compound O[C@@H]1[C@@H](O)[C@H](CO)O[C@H]1OC[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H]2[C@H]([C@H](OC[C@@H]3[C@@H]([C@H](OC4[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@H]5[C@@H]([C@@H](O[C@H]6[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@H]7[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O7)O)O6)O)[C@@H](O)[C@@H](CO)O5)O)O4)O)[C@@H](O)C(O[C@H]4[C@H]([C@@H](CO)O[C@@H](O)[C@@H]4O)O)O3)O)O[C@H](CO)[C@@H]2O)O)O1 RYHZSFNAGFOCEZ-PYXKSNNZSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 description 2
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 2
- PUQSUZTXKPLAPR-KSSYENDESA-N 4-(beta-D-Glucopyranosyloxy) benzyl alcohol Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1ccc(CO)cc1 PUQSUZTXKPLAPR-KSSYENDESA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 102000016938 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- 241000756943 Codonopsis Species 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 241000305492 Gastrodia Species 0.000 description 2
- PUQSUZTXKPLAPR-UJPOAAIJSA-N Gastrodin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(CO)C=C1 PUQSUZTXKPLAPR-UJPOAAIJSA-N 0.000 description 2
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 208000007443 Neurasthenia Diseases 0.000 description 2
- 206010029240 Neuritis Diseases 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 206010036105 Polyneuropathy Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 206010040943 Skin Ulcer Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000001773 anti-convulsant effect Effects 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 239000010231 banlangen Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000036995 brain health Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 229930193974 gastrodin Natural products 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- PUQSUZTXKPLAPR-NZEXEKPDSA-N helicidol Natural products O([C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](CO)O1)c1ccc(CO)cc1 PUQSUZTXKPLAPR-NZEXEKPDSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000002398 materia medica Substances 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000036284 oxygen consumption Effects 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 208000019629 polyneuritis Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001047 pyretic effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 201000008261 skin carcinoma Diseases 0.000 description 2
- 201000010153 skin papilloma Diseases 0.000 description 2
- 231100000019 skin ulcer Toxicity 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 235000015961 tonic Nutrition 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- PAFLSMZLRSPALU-MRVPVSSYSA-N (2R)-3-(3,4-dihydroxyphenyl)lactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-MRVPVSSYSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 206010003757 Atypical pneumonia Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010004663 Biliary colic Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- PAFLSMZLRSPALU-QMMMGPOBSA-N Danshensu Natural products OC(=O)[C@@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-QMMMGPOBSA-N 0.000 description 1
- 208000027219 Deficiency disease Diseases 0.000 description 1
- 241001523681 Dendrobium Species 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 241000208688 Eucommia Species 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 206010018045 Gastroptosis Diseases 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 239000000899 Gutta-Percha Substances 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 208000002979 Influenza in Birds Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 241000283956 Manis Species 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- NEEQFPMRODQIKX-REOHCLBHSA-N N(3)-oxalyl-L-2,3-diaminopropionic acid Chemical compound OC(=O)[C@@H](N)CNC(=O)C(O)=O NEEQFPMRODQIKX-REOHCLBHSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 240000000342 Palaquium gutta Species 0.000 description 1
- 241000590428 Panacea Species 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 244000179560 Prunella vulgaris Species 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241001601725 Sthenias Species 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 229930183118 Tanshinone Natural products 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 206010046814 Uterine prolapse Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 208000009257 Visceral Prolapse Diseases 0.000 description 1
- 206010063840 Visceroptosis Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241001251949 Xanthium sibiricum Species 0.000 description 1
- 206010048245 Yellow skin Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000003679 aging effect Effects 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002300 anti-fibrosis Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 206010064097 avian influenza Diseases 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000009172 bursting Effects 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 235000019994 cava Nutrition 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 201000004196 common wart Diseases 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 235000015177 dried meat Nutrition 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000000256 facial nerve Anatomy 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000002430 glycogenolytic effect Effects 0.000 description 1
- 229920000588 gutta-percha Polymers 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 208000024557 hepatobiliary disease Diseases 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 206010019847 hepatosplenomegaly Diseases 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- PYLWMHQQBFSUBP-UHFFFAOYSA-N monofluorobenzene Chemical compound FC1=CC=CC=C1 PYLWMHQQBFSUBP-UHFFFAOYSA-N 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 229940073020 nitrol Drugs 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 229960003371 protocatechualdehyde Drugs 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 239000012744 reinforcing agent Substances 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 235000011649 selenium Nutrition 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229930193551 sterin Natural products 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000009571 yupingfeng Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 235000016804 zinc Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8984—Dendrobium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8988—Gastrodia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种食疗粉及其制备方法，食疗粉以杜仲、天麻、三七、黄芪、铁皮石斛粉和燕麦粉等为原料，通过将天麻蒸熟后再采用工业加工技术把药食同源的中药材打细成粉，做成食疗粉进行食用。本发明的有益效果为：本发明的制备方法简单，制成的食疗粉具有活血化瘀、祛风降压、提高记忆力、补气降脂、益胃生津、养肝明目、強筋健骨、润滑关节、可增强胰岛素活性降血糖；提高机体免疫力、调节新陈代谢、延年益寿的功效。主治高血压、高血脂、高血糖、冠心病、静动脉硬化、中风偏瘫、老年痴呆；血脂异常、肥胖、痛风：肿瘤患者放化疗后的康复治疗及减轻副作用；胃肠不适、神疲、乏力、头晕、失眠或睡眠质量差等的治疗。
Description
技术领域
本发明属于保健品加工领域，具体涉及一种食疗粉及其制备方法。
背景技术
经历了2002年的非典型肺炎，使国人们认识到中医药在抗病毒方面的强大优势，其独特的疗效也引起世界的关注，并得到世界卫生组织(WHO)专家的肯定。迄今为止，已有70多种中药组方被公诸于世。但是，这些组方大都成分复杂，例如CN200810102746.8披露一种防治畜禽病毒性疾病的复方药物组合物，其由连翘、板蓝根、竹叶、黄芩、金银花/山银花、大青叶、黄芪、淫羊霍、女贞子、生地、丹参、川芎、乌梅、葶苈子、川贝、陈皮、麦冬、甘草、氟苯尼考等制成。CN200710071952.2披露一种抗禽流感病毒的中药，其由贯众8～10份、板蓝根8～10份、黄芪15～20份、柴胡8～10份、连翘5～8份、黄连8～10份、金银花/山银花8～10份、黄芩8～10份和甘草4～6份制成。中医药作为我国独特的卫生资源、潜力巨大的经济资源、具有原创优势的科技资源、优秀的文化资源和重要的生态资源，在经济社会发展中发挥着重要作用。随着我国新型工业化、信息化、城镇化、农业现代化、中医药现代化深入发展，人口老龄化进程加快，健康服务业蓬勃发展，人民群众对中医药服务的需求越来越旺盛，迫切需要继承、发展、利用好中医药，充分发挥中医药在深化医药卫生体制改革中的作用，造福人类健康。当前，我国进入全面建成小康社会决胜阶段，满足人民群众对简便验廉的中医药服务需求，迫切需要大力发展健康服务业，拓宽中医药服务领域。深化医药卫生体制改革，加快推进健康中国建设，迫切需要在构建中国特色基本医疗制度中发挥中医药独特作用。适应未来医学从疾病医学向健康医学转变、医学模式从生物医学向生物—心理—社会模式转变的发展趋势，迫切需要继承和发展中医药的绿色健康理念、天人合一的整体观念、辨证施治和综合施治的诊疗模式、运用自然的防治手段和全生命周期的健康服务。
但现有技术存在一些缺陷：煎药麻烦、中药味浓口感不佳；目前我国用中药辅助治疗三高及亚健康病人康复的药品很少；大多数药物有副作用，不能长期服用。
发明内容
为了解决现有技术存在的上述问题，本发明提供了一种食疗粉及其制备方法。本发明的食疗粉可以长期食用，无副作用；辅助治疗三高、亚健康人、肿瘤病人。
本发明所采用的技术方案为：一种食疗粉，包括以下重量份的原料：杜仲2-8份、天麻4-10份、三七4-7份、黄芪4-9份、燕麦粉6-16份、铁皮石斛1-9份、红薯粉2-8份。
进一步地，还包括铁皮石斛1-9份、山楂3-7份、丹参3-9份。
一种所述的食疗粉的制备方法，包括以下步骤：
(1)蒸制：将天麻洗净后进行蒸制，然后进行真空干燥，形成干制天麻；
(2)粉碎：将所述干制天麻进行粉碎，形成天麻粉；将杜仲、铁皮石斛、三七和黄芪分别粉碎，形成杜仲粉、铁皮石斛粉、三七粉和黄芪粉；
(3)混合：将所述天麻粉与杜仲粉、铁皮石斛粉、三七粉、黄芪粉进行第一次混合，形成第一次混合料；再将所述第一次混合料与剩余的其他原料进行第二次混合，形成混合粉；
(4)干燥：将所述混合粉进行真空干燥，即得成品。
进一步地，步骤(1)中所述蒸制的温度为95-100℃，所述蒸制的时间为10-30分钟。将天麻蒸熟即可。
进一步地，步骤(2)中所述天麻粉、杜仲粉、三七粉和黄芪粉的颗粒细度均为200-300μm。
进一步地，步骤(1)和步骤(4)中所述的真空干燥的真空度均为90-98.5KPa，所述真空干燥的温度均为60-70℃；所述真空干燥的时间均为5-8小时。
进一步地，步骤(1)和步骤(4)中所述的真空干燥均为干燥至含水量为7％以下。
本发明制备的食疗粉可以是片剂、胶囊剂、颗粒剂、糖浆剂、糊剂、丸剂等。
用法用量：本发明的食疗粉可以作为为保健品长期服用，也可作为治疗药物进行服用，用法与用量如下：
(1)保健服用：每天一次，用本发明的食疗粉2-8g与水、鹅蛋/鸭蛋/鸡蛋混合后共同蒸熟服用；也可以用水、鹅蛋/鸭蛋/鸡蛋类、红薯粉、荞麦、燕麦一起蒸12分钟左右成蛋糕、吃起来没有浓浓的中药味。
(2)治疗服用：每天两次，每次用本粉2-8g用开水冲服，早晚各一次。
本发明制备的食疗粉在生产时所用的原料中大部分是经规范炮制加工后的“中药饮片”。本发明中所用原料的性能和功用如下：
杜仲：补肝肾，强筋骨的良药，杜仲的树皮、树枝、树叶均含有杜仲胶，所以折断时有银白色的弹性白丝相连，胶丝多而密，银白色，富有弹性，可拉至1～3厘米才断，故有“丝连木”之称。杜仲味苦，微臭，嚼之始有颗粒感，后棉花感。降三高效果好杜仲不但是传统的名贵中药材，现代医学研究还验证了杜仲还是一服对付“三高”的“好武器”。医学研究证明，杜仲是世界上最高质量的天然降压药物。杜仲含有的多种药用成分，能加快血流速度，改善机体微循环功能，不但使它具有良好的降压作用，有效改善由高血压引起的头晕、失眠等症状，而且还有助于正常人预防血压升高的发生。对于降血糖方面，专家指出，从杜仲可分离的成分中能得到5种α-葡萄糖苷酶抑制成分，它们可以阻碍或延迟葡萄糖的生成以及肠道的吸收，从而维持体内适当的血糖值，具有较好的降血糖作用。因此，杜仲可作为糖尿病及肥胖者理想的一种食疗用品。
此外，常吃杜仲还能减少人体对坏胆固醇(低密度脂蛋白胆固醇)的吸收，并升高好胆固醇(高密度脂蛋白)。
降三高用法对于只是血压高而血糖、血脂正常的人来说，在寒冷的冬季，可以经常用10克杜仲、10克枸杞子、栗子10枚和100克大米煮粥，用于晚餐时食用，不但有助于降压暖胃，还有一定益气健脾的功效。如果是高血压兼有高血脂或高血糖，用10克杜仲，5克山楂，水煎后代茶饮。长期饮用能收到良好的降压、降脂、降糖，以及润肠通便的作用。此外，杜仲叶也有同样的降“三高”作用，用15克杜仲叶，10克白菊花，用水浸泡，代茶饮，或是15克杜仲叶和10克夏枯草，水煎1小时后，取药液代茶饮，都能收到很好的降压效果。而用杜仲叶和银杏叶水煎代茶饮，则是活血降脂的绝佳饮品。
天麻：天麻润而不燥，主入肝经，长于平肝息风，凡肝风内动、头目眩晕之症，不论虚实，均为要药。平肝息风：天麻质润多液，能养血息风，可治疗血虚肝风内动的头痛、眩晕，亦可用于小儿惊风、癫痫、破伤风；用于风痰引起的眩晕、偏正头痛、肢体麻木、半身不遂。天麻适合用于内风所致的头晕。内风引起头痛的三种类型：肝阳上亢型、痰浊中阻和肾虚病人。天麻对感冒引起的头痛头晕不合适。天麻有镇静、镇痛、抗惊厥作用；能增加脑血流量，降低脑血管阻力，轻度收缩脑血管，增加冠状血管流量；能降低血压，减慢心率，对心肌缺血有保护作用；天麻多糖有免疫活性。镇痛作用，用天麻制出的天麻注射液，对三叉神经痛、血管神经性头痛、脑血管病头痛、中毒性多发性神经炎等，有明显的镇痛效果。近年来，经一些医疗单位1000多例患者的临床试用，有效率达90％；镇静作用，有的医疗单位用合成天麻素(天麻甙)治疗神经衰弱和神经衰弱综合症病人，有效率分别为89.44％和86.87％。且能抑制咖啡因所致的中枢兴奋作用，还有加强戊巴比妥纳的睡眠时间效应；抗惊厥作用，天麻对面神经抽搐、肢体麻木、半身不遂、癫痫等的一定疗效。还有缓解平滑肌痉挛，缓解心绞痛、胆绞痛的作用；降低血压作用，天麻能治疗高血压。久服可平肝益气、利腰膝、强筋骨，还可增加外周及冠状动脉血流量，对心脏有保护作用；明目、增智作用，天麻尚有明目和显著增强记忆力的作用。天麻对人的大脑神经系统具有明显的保护和调节作用，能增强视神经的分辨能力，目前已用作高空飞行人员的脑保健食品或脑保健药物。日本用天麻注射液治疗老年痴呆症，有效率达81％。
三七粉：富含三七皂苷、三七多糖、三七素、黄酮有效成分，具有止血、活血化瘀、消肿定痛、滋补强壮、抗疲劳、耐缺氧、抗衰老、降血脂、降血糖、提高机体免疫功能等作用。治疗高血脂，以三七粉末，每日服3次，每日服0.6克，饭前用温开水冲服，一般1至2个月为1疗程，此法对冠心病、高血压病、脑动脉硬化症伴有血脂及胆固醇增高患者有效，其总脂及胆固醇均有明显下降；治疗胃出血，以三七粉末，每日服3次，每次数1.5克，用温开水冲服。此法可治疗各种类型的胃出血；治疗心绞痛，三七粉末，每日2次，每次6克温开水冲服，效果颇佳，经此法治疗的有的原长期服用复方硝酸甘油片者，服用三七后即可停服；有的合并高血压者，服后血压缓缓下降，此法服用时间为15至30天；治疗冠心病，可用三七每日3次，每次1克，30天为一疗程，三七中所含的三七皂甙和黄酮类等有效成分，有明显的强心和扩张血管，增强冠状动脉血流量，降低动脉压减少心肌耗氧量的作用；治顽固性头痛，按规定剂量，开始时先服用三七片5片，此后每天相隔6小时服2次，可以止痛，三七治顽固性头痛机理主要是活血化瘀、疏经通络、祛风除湿；降低血脂，用生三七粉每日3次，每次0.6克，饭前服，30天为一疗程，能有效地降低血脂和血清胆固醇，尤其能明显地降低三酸甘油脂的含量；去寻常疣，让13例青年寻常疣患者服用三七粉，每日3次，每次0.5～1克。一般服用20～30天左右即痊愈，有效率达93％左右；降低血清谷丙转氨酶，空腹服用三七粉，每日3次，每次1克，治疗肝胆疾患及原因不明的谷丙转氨酶增高，还可改善慢性肝炎的血浆蛋白，抗癌，三七能增强机体免疫系统防御功能。日本医学家给移植皮肤癌小白鼠食用从三七中提取的三七多糖A，结果治愈了小白鼠的皮肤癌。他们给患有肉瘤－180的小鼠食用三七多糖A，两星期后肿瘤缩小，5个星期后60％的小鼠肉瘤消失。他们认为，三七多糖A对人体子宫颈癌的抑制率高达90％。
天麻和三七协同作用，治头痛效果好，天麻和三七都有治疗头痛功能，且效果都非常好，这二款中药材可以同天食用，同时服用目前也没有发现什么不适，但最好分开吃。服用方法，可以熬水喝，也可以研末服用。用量：天麻一天10克左右，三七粉一天3克左右即可，均饭后服用。清代名医赵学敏在他所著的《本草纲目拾遗》中说：“人参补气第一，三七补血第一，味同而功亦等”，称三七为“中药之最珍贵者”。现代研究发现，三七的化学成分、药理作用和临床应用与人参有相似之处。其人参总皂甙含量超过人参。三七可扩张血管，降低血管阻力，增加心输出量，减慢心率，降低心肌耗氧量和毛细血管的通透性，在心血管病防治方面比人参有明显的优势。
黄芪：又名黄耆，植物黄芪产于内蒙古、山西、甘肃、黑龙江等地，为国家三级保护植物。中药材黄芪为豆科草本植物蒙古黄芪、膜荚黄芪的根，具有补气固表、利水退肿、托毒排脓、生肌等功效。黄芪的药用迄今已有2000多年的历史，现代研究，黄芪含皂甙、蔗糖、多糖、多种氨基酸、叶酸及硒、锌、铜等多种微量元素。有增强机体免疫功能、保肝、利尿、抗衰老、抗应激、降压和较广泛的抗菌作用。但表实邪盛，气滞湿阻，食积停滞，痈疽初起或溃后热毒尚盛等实证，以及阴虚阳亢者，均须禁服。用于脾胃气虚；脾气虚，中气下陷，脏器下垂(脱肛、子宫脱垂、胃下垂等)；肺气虚弱，咳喘短气；气虚自汗，易于感冒；气虚水肿，小便不利；气血不足，贫血萎黄，或肢体麻木，或疮疡、创作不易愈合；消渴(糖尿病)。补气固表，利尿托毒，排脓，敛疮生肌。用于气虚乏力，食少便溏，中气下陷，久泻脱肛，便血崩漏，表虚自汗，气虚水肿黄芪圆片，痈疽难溃，久溃不敛，血虚痿黄，内热消渴；慢性肾炎蛋白尿，糖尿病。敛汗补气固表，表虚自汗，多用于体虚表弱所致的自汗。如表气不固，外感风寒而汗出，用黄芪配白术、防风治之，久服必效。方如玉屏风散；也可配浮小麦、麻黄，阴虚盗汗，可与生地、麦冬等滋阴药同用。利水消肿，急性肾炎水肿，用于阳气不足所致的虚性水肿，并常与防已、茯苓、白术等合而用之，方如防己黄芪汤；慢性肾炎水肿、脾肾虚者，常与党参、白术、茯苓同用。托疮排脓，阳气虚弱，用于疮疡久不溃破而内陷，有促进溃破及局限作用。痈疽久不穿头，常与穿山甲、皂角刺、当归、川芎同用；疮疡久溃不愈，用于疮疡溃破后，久不收口，有生肌收口之作用，且常配银花、皂刺、地丁等。脓液清稀，常与党参、肉桂等同用。此外，黄芪还应用于糖尿病、脑血管意外后遗症、高血压病、风湿病、多发性神经炎、肌无力症等多种疾病。药材来源药材基源为豆科草本植物蒙古黄芪、膜荚黄芪的根。黄芪适宜产区为内蒙古、甘肃、宁夏、山西、河北、陕西，其中又以内蒙古武川黄芪的品质最好，多种有效成分指标均超过国家标准，本发明采用妙玉堂黄芪片是黄芪中品质最好的大斜片。黄芪始载于《神农本草经》。古代写作黄耆，李时珍在《本草纲目》中释其名曰：“耆，长也。黄耆色黄，为补药之长，故名。”黄芪是传统疮药，有生肌的作用，尤其适用于“久败疮”，即溃疡久不愈合的化脓性感染。其表现为脓水清稀，创面平塌、全身状况差。现代中医外科名医赵炳南先生有黄芪膏一方，用黄芪浓煎成膏，加入等量蜂蜜，混均匀后备用。表实邪盛，气滞湿阻，食积停滞，痈疽初起或溃后热毒尚盛等实证。中医认为“脾为后天之本”。脾胃派代表人物李杲认为黄芪“益元气而补三焦”，清代的黄宫绣称黄芪为“补气诸药之最”。现代研究发现，黄芪不仅能扩张冠状动脉，改善心肌供血，提高免疫功能，而且能够延缓细胞衰老的进程。
铁皮石斛：具有免疫调节功能，人体的免疫调节作用是大多数活性多糖的共同作用，是它们发挥其他生理和药理作用的基础。现代药理学研究分析表明，铁皮石斛茎中的黏性物质主要是水溶性多糖，含量占其干重的比例高达25％以上，它是一类免疫增强剂，对提高外周白细胞和促进淋巴细胞产生移动因子具有明显的作用，在实验条件下，还可以消除免疫抑制剂环磷酰胺的副作用，临床实验也证明铁皮石斛多糖对调节机体免疫力有非常显著的作用；降血糖功能，糖尿病，中医称“消渴症”，是一种因胰腺分泌不足引起的代谢性疾病，长期服用西药降血糖、注射胰岛素、有副作用。经研究证明，铁皮石斛能显著降低机体的血糖值，能促进胰岛素分泌和抑制胰高血糖素分泌，铁皮石斛与口服降血糖药磺酰脲类不同，它对正常血糖无降低作用，也不提高血清胰岛素水平，且对胰岛细胞具有修复作用；同时铁皮石斛多糖还具有胰外降血糖的作用，通过抑制肾上腺素引起的肝糖原分解和促进肝糖原合成，从而可减少血糖的来源，增加血糖的去路，达到降低血糖值的目的；抗氧化、抗衰老功能，经研究发现许多活性多糖具有清除自由基、提高抗氧化酶活性和抑制脂质过氧化的活性，起到保护生物膜和延缓衰老的作用。石斛含有较高活性的超氧化物歧化酶(SOD)、过氧化物酶(POD)、过氧化氢酶(CAT)，具有较强的抗氧化能力，且在碱性条件下石斛多糖具有较好的抗氧化活性。实验表明，石斛能显著提高超氧化物歧化酶(SOD)和血清钖羟脯氨酶(HYP)的水平，明显降低脂质过氧化物(LOP)和单胺氧化物(MAO)，从而起到抗衰老作用。铁皮石斛中除了富含多糖，还富含多种生物碱、氨基酸及淀粉等成分。这些成分的药理作用虽相互联系却又存在一定的差别，如：生物碱主要作用在于“抗肿瘤、对心血管疾病、抑制胃肠道疾病、止痛退热”等；酚类化合物主要表现在抗衰老等方面；而铁皮石斛中的多糖，其药理作用主要表现在“提高免疫力免疫、降血糖以及抗衰老”等方面。铁皮石斛的作用相当的广，所以，《神农本草经》将铁皮石斛列为具有“轻身延年”作用的圣药，它易被人体吸收，滋养全身，让身体各脏器运转自如，肌肤润泽，气血通畅，经过一段时间后，更能让人摆脱疾病的困扰，重新焕发青春的光彩。
山楂：用于肉食积滞，胃脘胀满，泻痢腹痛，瘀血经闭，产后瘀阻，心腹刺痛，疝气疼痛；高脂血症。
丹参：味苦，性微寒；归心、肝经。活血调经，祛瘀止痛，凉血消痈，清心除烦，养血安神。含丹参酮、原儿茶醛、原儿茶酸、丹参素、维生素E等。主治月经不调，经闭痛经，症瘕积聚，胸腹刺痛，热痹疼痛，疮疡肿痛，心烦不眠；肝脾肿大，心绞痛。活血能扩张冠状动脉，增加冠脉流量，改善心肌缺血、梗塞和心脏功能，调节心律，并能扩张外周血管，改善微循环；缩短红细胞及血色素的恢复期，使网织细胞增多，能促进组织的修复，加速骨折的愈合；能提高机体耐缺氧能力；预防血栓有抗凝血，促进纤溶，抑制血小板凝聚，抑制血栓形成的作用；降血脂能降低血脂，抑制冠脉粥样硬化形成；护肝能抑制或减轻肝细胞变性、坏死及炎症反应，促进肝细胞再生，并有抗纤维化作用；另外，对结核杆菌等多种细菌有抑制作用；抗肿瘤能有中枢神经有抑制作用；有抗肿瘤作用；能增强机体免疫功能；降血糖能降低血糖。
本发明的有益效果为：本发明所用的制备方法简单，通过将天麻蒸熟后再采用工业加工技术把药食同源的中药材打细成粉，做成食疗粉进行食用，无副作用；主要采用食疗方法辅助治疗三高、亚健康人、肿瘤病人。制成的食疗粉具有活血化瘀、祛风降压、提高记忆力、补气降脂、益胃生津、养肝明目、強筋健骨、润滑关节、可增强胰岛素活性降血糖；提高机体免疫力、调节新陈代谢、延年益寿的功效。主治高血压、高血脂、高血糖、冠心病、静动脉硬化、中风偏瘫、老年痴呆；血脂异常、肥胖、痛风；肿瘤患者放化疗后的康复治疗及减轻副作用；胃肠不适、神疲、乏力、头晕、失眠或睡眠质量差等的治疗。
具体实施方式
下面结合具体实施例对本发明的技术方案和效果做进一步详细说明。
如无特别意外说明，本发明中使用的各原料皆为行业通用原料。
实施例1
一种食疗粉，由以下原料制成：杜仲2g、天麻4g、三七7g、黄芪4g、燕麦粉16g、铁皮石斛9g、红薯粉2g。
制备方法，包括以下步骤：
(1)蒸制：将天麻洗净后进行蒸制，蒸熟后进行真空干燥，形成干制天麻；
(2)粉碎：将所述干制天麻进行粉碎，形成天麻粉；将杜仲、铁皮石斛、三七和黄芪分别粉碎，形成杜仲粉、铁皮石斛粉、三七粉和黄芪粉；
(3)混合：将所述天麻粉与杜仲粉、铁皮石斛粉、三七粉、黄芪粉进行第一次混合，形成第一次混合料；再将所述第一次混合料与剩余的其他原料进行第二次混合，形成混合粉；
(4)干燥：将所述混合粉进行真空干燥，即得成品。
实施例2
一种食疗粉，由以下原料制成：
杜仲8g、天麻10g、三七4g、黄芪9g、燕麦粉6g、铁皮石斛16g、红薯粉8g；铁皮石斛6g、山楂7g、丹参9g。
制备方法，包括以下步骤：
(1)蒸制：将天麻洗净后在95℃下进行蒸制30分钟，蒸熟后在真空度为90KPa，温度为70℃的条件下进行真空干燥5小时，干燥至含水量为7％形成干制天麻；
(2)粉碎：将所述干制天麻进行粉碎，形成颗粒细度为300μm的天麻粉；将杜仲、铁皮石斛、三七和黄芪分别粉碎，形成颗粒细度均为300μm的杜仲粉、铁皮石斛粉、三七粉和黄芪粉；
(3)混合：将所述天麻粉与杜仲粉、铁皮石斛粉、三七粉、黄芪粉进行第一次混合，形成第一次混合料；再将所述第一次混合料与剩余的其他原料进行第二次混合，形成混合粉；
(4)干燥：将所述混合粉在真空度为90KPa，温度为70℃的条件下进行真空干燥8小时，干燥至含水量为6％即得成品。
实施例3
一种食疗粉，由以下原料制成：
杜仲5g、天麻6g、三七5g、黄芪6g、燕麦粉10g、铁皮石斛1g、红薯粉5g；铁皮石斛1g、山楂3g、丹参3g。
制备方法，包括以下步骤：
(1)蒸制：将天麻洗净后在100℃下进行蒸制10分钟，蒸熟后在真空度为98.5KPa，温度为60℃的条件下进行真空干燥8小时，干燥至含水量为5％形成干制天麻；
(2)粉碎：将所述干制天麻进行粉碎，形成颗粒细度为200μm的天麻粉；将杜仲、铁皮石斛、三七和黄芪分别粉碎，形成形成颗粒细度均为200μm的杜仲粉、铁皮石斛粉、三七粉和黄芪粉；
(3)混合：将所述天麻粉与杜仲粉、铁皮石斛粉、三七粉、黄芪粉进行第一次混合，形成第一次混合料；再将所述第一次混合料与剩余的其他原料进行第二次混合，形成混合粉；
(4)干燥：将所述混合粉在真空度为98.5KPa，温度为60℃的条件下进行真空干燥5小时，干燥至含水量为4％即得成品。
食疗粉可以制成片剂、胶囊剂、颗粒剂、糖浆剂、糊剂、丸剂等。
用法用量：本发明的食疗粉可以作为为保健品长期服用，也可作为治疗药物进行服用，用法与用量如下：
(1)保健服用：每天一次，用本发明的食疗粉2-8g与水、鹅蛋/鸭蛋/鸡蛋混合后共同蒸熟服用；也可以用水、鹅蛋/鸭蛋/鸡蛋类、红薯粉、荞麦、燕麦一起蒸12分钟左右成蛋糕，吃起来没有浓浓的中药味。
(2)治疗服用：每天两次，每次用本粉2-8g用开水冲服，早晚各一次。
上述实施例配方是发明人经过多次试验研究的结果，经试用，对高血压、高血脂、高血糖、冠心病、静动脉硬化、中风偏瘫、老年痴呆等都能起到较好的疗效。以临床使用60例为例，其中：糖尿病患者伴有高血脂20例，高血压患者伴有高血脂20例；血糖、血压、血脂都偏高的20例。
糖尿病患者伴有高血脂20例：
将本发明实施例3的食疗粉，每天两次，每次3g，与水、鹅蛋/鸭蛋/鸡蛋、红薯粉、荞麦、燕麦一起蒸12分钟成蛋糕服用，连服3个月，18例患者血糖到了正常值，1例也明显下降，1例作用不明显。总有效率达95.0％，治愈率为90.0％，无作用5.0％。
高血压患者伴有高血脂20例：
将本发明实施例1的食疗粉，每天两次，每次5g与水、鹅蛋/鸭蛋/鸡蛋混合后共同蒸熟服用，连服3个月，16例患者血压到了正常值，1例也明显下降，3例作用不明显。总有效率达85.0％，治愈率为80.0％，无作用15％。
血糖、血压、血脂都偏高的20例：
将本发明实施例2的食疗粉，每天两次，每次8g，用开水冲服，早晚各一次，连饮3个月，10例患者血糖、血压、血脂到了正常值(三项指标都达到健康标准)，6例也明显下降，4例作用不明显。总有效率达80.0％，治愈率为50.0％，无作用20.0％。
本发明不局限于上述最佳实施方式，任何人在本发明的启示下都可得出其他各种形式的产品，但不论在其形状或结构上作任何变化，凡是具有与本申请相同或相近似的技术方案，均落在本发明的保护范围之内。
Claims (7)
1.一种食疗粉，其特征在于，包括以下重量份的原料：杜仲2-8份、天麻4-10份、三七4-7份、黄芪4-9份、燕麦粉6-16份、铁皮石斛1-9份、红薯粉2-8份。
2.根据权利要求1所述的食疗粉，其特征在于，还包括铁皮石斛1-9份、山楂3-7份、丹参3-9份。
3.一种如权利要求1或2所述的食疗粉的制备方法，其特征在于，包括以下步骤：
(1)蒸制：将天麻洗净后进行蒸制，然后进行真空干燥，形成干制天麻；
(2)粉碎：将所述干制天麻进行粉碎，形成天麻粉；将杜仲、铁皮石斛、三七和黄芪分别粉碎，形成杜仲粉、铁皮石斛粉、三七粉和黄芪粉；
(3)混合：将所述天麻粉与杜仲粉、铁皮石斛粉、三七粉、黄芪粉进行第一次混合，形成第一次混合料；再将所述第一次混合料与剩余的其他原料进行第二次混合，形成混合粉；
(4)干燥：将所述混合粉进行真空干燥，即得成品。
4.根据权利要求3所述的食疗粉的制备方法，其特征在于，步骤(1)中所述蒸制的温度为95-100℃，所述蒸制的时间为10-30分钟。
5.根据权利要求3所述的食疗粉的制备方法，其特征在于，步骤(2)中所述天麻粉、杜仲粉、三七粉和黄芪粉的颗粒细度均为200-300μm。
6.根据权利要求3所述的食疗粉的制备方法，其特征在于，步骤(1)和步骤(4)中所述的真空干燥的真空度均为90-98.5KPa，所述真空干燥的温度均为60-70℃；所述真空干燥的时间均为5-8小时。
7.根据权利要求3所述的食疗粉的制备方法，其特征在于：步骤(1)和步骤(4)中所述的真空干燥均为干燥至含水量为7％以下。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611029647.2A CN106389892A (zh) | 2016-11-14 | 2016-11-14 | 一种食疗粉及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611029647.2A CN106389892A (zh) | 2016-11-14 | 2016-11-14 | 一种食疗粉及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106389892A true CN106389892A (zh) | 2017-02-15 |
Family
ID=58081390
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611029647.2A Pending CN106389892A (zh) | 2016-11-14 | 2016-11-14 | 一种食疗粉及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106389892A (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107853693A (zh) * | 2017-11-17 | 2018-03-30 | 广西顺昌隆生物科技有限公司 | 一种铁皮石斛代餐粉及其制备方法 |
| CN115088841A (zh) * | 2022-06-17 | 2022-09-23 | 王常清 | 一种降血糖食疗配方及其制作方法 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101357193A (zh) * | 2008-08-22 | 2009-02-04 | 朱秀进 | 一种治疗高血压高血脂的中药及其制备方法 |
| CN102302684A (zh) * | 2011-09-23 | 2012-01-04 | 唐红芳 | 三七活血通片 |
| CN104115950A (zh) * | 2014-05-15 | 2014-10-29 | 王腾鉴 | 一种降脂、降压、降糖的三降茶 |
| CN104922470A (zh) * | 2015-05-28 | 2015-09-23 | 许江 | 一种抗氧化清脂的组合物及其制备方法 |
| CN105963556A (zh) * | 2016-05-31 | 2016-09-28 | 安徽皖斛堂生物科技有限公司 | 一种健胃益脾降血压的铁皮石斛药酒及其制备方法 |
| CN106036842A (zh) * | 2016-05-31 | 2016-10-26 | 安徽皖斛堂生物科技有限公司 | 一种适用于三高人群的保健冲剂及其制备方法 |
-
2016
- 2016-11-14 CN CN201611029647.2A patent/CN106389892A/zh active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101357193A (zh) * | 2008-08-22 | 2009-02-04 | 朱秀进 | 一种治疗高血压高血脂的中药及其制备方法 |
| CN102302684A (zh) * | 2011-09-23 | 2012-01-04 | 唐红芳 | 三七活血通片 |
| CN104115950A (zh) * | 2014-05-15 | 2014-10-29 | 王腾鉴 | 一种降脂、降压、降糖的三降茶 |
| CN104922470A (zh) * | 2015-05-28 | 2015-09-23 | 许江 | 一种抗氧化清脂的组合物及其制备方法 |
| CN105963556A (zh) * | 2016-05-31 | 2016-09-28 | 安徽皖斛堂生物科技有限公司 | 一种健胃益脾降血压的铁皮石斛药酒及其制备方法 |
| CN106036842A (zh) * | 2016-05-31 | 2016-10-26 | 安徽皖斛堂生物科技有限公司 | 一种适用于三高人群的保健冲剂及其制备方法 |
Non-Patent Citations (2)
| Title |
|---|
| 屠庆祝等: "中药治疗高血压的用药规律探要", 《实用中医内科杂志》 * |
| 屠庆祝等: "浅谈中药治疗糖尿病的用药规律", 《中医药临床杂志》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107853693A (zh) * | 2017-11-17 | 2018-03-30 | 广西顺昌隆生物科技有限公司 | 一种铁皮石斛代餐粉及其制备方法 |
| CN115088841A (zh) * | 2022-06-17 | 2022-09-23 | 王常清 | 一种降血糖食疗配方及其制作方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103053748B (zh) | 一种葛根降脂降糖保健茶及其制备方法 | |
| CN102988638B (zh) | 一种青钱柳叶降脂降糖保健茶及其制备方法 | |
| CN104208302A (zh) | 一种降血脂的金樱子保健口服液及其制备方法 | |
| CN102172385A (zh) | 一种具有增强免疫力、降血糖和降血脂作用的中药制剂 | |
| CN103977358A (zh) | 一种降脂护肝的口服中药 | |
| CN104905267A (zh) | 一种决明子降血脂保健口服液及其制备方法 | |
| CN103301267A (zh) | 一种治疗高血压和/或动脉粥样硬化的中药组合物及应用 | |
| CN106389892A (zh) | 一种食疗粉及其制备方法 | |
| CN103749819A (zh) | 一种降糖降脂的山茱萸保健茶及其制备方法 | |
| CN101095798B (zh) | 一种治疗白发病的中药药物 | |
| CN102210839A (zh) | 一种治疗冠心病的中药胶囊 | |
| CN104857210A (zh) | 一种治疗脂肪肝的中药组合制剂及其制备方法 | |
| CN105796971A (zh) | 一种治疗脂肪肝的中药制剂及其制作方法 | |
| CN105362630A (zh) | 一种治疗更年期综合症的药物组合物及其制备方法 | |
| CN105056090A (zh) | 一种治疗高血压的中药剂及其制备方法 | |
| CN103705733A (zh) | 一种治疗心律不齐的中药胶囊及其制备方法 | |
| CN103520644B (zh) | 用于治疗痰瘀型高脂血症的中药组合物及其制备方法 | |
| CN108310212A (zh) | 一种用于延缓衰老的药物及其制备方法和应用 | |
| CN102526542A (zh) | 一种治疗胰腺癌症的中药制剂 | |
| CN107034094A (zh) | 一种舒筋通络蜂蜜保健酒的制备方法 | |
| CN106581425A (zh) | 一种采用调气活血法治疗糖尿病的药物组合物 | |
| CN106107434A (zh) | 一种开胃健身凉皮及其制备方法 | |
| CN105362706A (zh) | 金钗石斛清热凉茶 | |
| CN104998131A (zh) | 可用于促进伤骨愈合的组合物及其制备方法 | |
| CN105288095A (zh) | 一种治疗糖尿病的中药组合物及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170215 |
|
| RJ01 | Rejection of invention patent application after publication |